Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases.
about
Upstream open reading frames: molecular switches in (patho)physiologyLate-life rapamycin treatment reverses age-related heart dysfunction.Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.Critical illness-induced bone loss is related to deficient autophagy and histone hypomethylation.Changing glucocorticoid action: 11β-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation.Tetradecylthioacetic acid inhibits proliferation of human SW620 colon cancer cells--gene expression profiling implies endoplasmic reticulum stress.Pivotal regulatory network and genes in osteosarcomaEmerging drugs for the treatment of bone metastasis.Investigational serine/threonine kinase inhibitors against prostate cancer metastases.Metabolic regulation of osteoclast differentiation and function.Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation.CCAAT enhancer-binding proteins have long boney fingers.Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis.C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
P2860
Q24614000-A6FEABBE-23F4-43D7-AF38-15B6C6A9584DQ33903651-4D993EA5-BD40-485F-816D-9BA70C3FB99EQ35113761-FDD47594-9A6B-4F6E-99C3-AA82BEEE0C2FQ35780085-059B7781-5121-47DB-BE78-D830FE18D8ECQ38084054-C530FD36-526A-4983-91AB-F5739184731BQ38330840-07C18966-A4F9-483A-B2BD-187FBD23AEAFQ38488094-2F5C9D4B-9B7F-4FA2-AC76-B2926A30C296Q38538263-92EF5392-AF9A-47F9-862D-4BFAC20D4ADFQ39021945-D2F3DD35-53FB-401D-B752-9F951D1F94CBQ51005199-89524786-9D57-4BB6-8867-B717D66B8E42Q51063770-4AB5A49F-C6F2-4445-9CED-4CA71D3E4895Q52891201-767F6358-B36A-4112-9255-82C26941C39AQ52891891-252C627A-A718-4AAB-BA70-1259541E5E24Q53689778-B4AC678E-EB67-4193-9E68-0892957D6FFFQ58795101-051BD15A-17FE-41CB-805E-04BCAC92714A
P2860
Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Rapamycin and the transcriptio ...... tions for lytic bone diseases.
@en
Rapamycin and the transcriptio ...... tions for lytic bone diseases.
@nl
type
label
Rapamycin and the transcriptio ...... tions for lytic bone diseases.
@en
Rapamycin and the transcriptio ...... tions for lytic bone diseases.
@nl
prefLabel
Rapamycin and the transcriptio ...... tions for lytic bone diseases.
@en
Rapamycin and the transcriptio ...... tions for lytic bone diseases.
@nl
P2860
P921
P1476
Rapamycin and the transcriptio ...... tions for lytic bone diseases.
@en
P2093
Jeske J Smink
P2860
P2888
P304
P356
10.1007/S00109-009-0567-8
P50
P577
2009-11-27T00:00:00Z
2010-03-01T00:00:00Z